Treatment with GRI-0621, an experimental oral therapy from GRI Bio, boosts lung function in adults with idiopathic pulmonary…
Articles by Steve Bryson, PhD
A novel inhalable therapy has shown promise for treating idiopathic pulmonary fibrosis (IPF) by outperforming an approved oral medicine…
Blocking caspase-9 — an enzyme involved in programmed cell death, or apoptosis — may halt or reverse tissue scarring in…
Treatment with Trevi Therapeutics’ nalbuphine extended-release (ER) tablets significantly reduced daily coughing frequency in people with idiopathic pulmonary…
Let-7, an established tumor suppressor microRNA that controls gene activity, plays a key role in lung tissue repair and the…
Nerandomilast, Boehringer Ingelheim’s investigational oral therapy, significantly slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF)…
A cancer immunotherapy known as ipilimumab was able to reduce scar formation and promote tissue regeneration in the lungs of…
Blocking Piezo2, a protein receptor that senses mechanical forces in tissues — ones such as stress, strain, and stiffness —…
An imbalance in gene activity within two types of immune cells explains why idiopathic pulmonary fibrosis (IPF) progresses but…
Blocking fatty acid synthase (FASN), an enzyme responsible for fatty acid production in cells, reduced the signs of induced…